Difference between revisions of "Team:CCU Taiwan/Human Practices"

m
m
Line 268: Line 268:
 
                     <img id="imginfo1" src="https://static.igem.org/mediawiki/2020/5/59/T--CCU_Taiwan--HP_3_4.jpg">
 
                     <img id="imginfo1" src="https://static.igem.org/mediawiki/2020/5/59/T--CCU_Taiwan--HP_3_4.jpg">
 
                 </div>
 
                 </div>
                <br>
 
 
                 <li><b>Dr. Sugi Guthula</b> (Ph.D. in Chemistry and Biochemistry, expert in applications of nanoplasmonic biosensors)</li>
 
                 <li><b>Dr. Sugi Guthula</b> (Ph.D. in Chemistry and Biochemistry, expert in applications of nanoplasmonic biosensors)</li>
 
                 <p>Dr. Guthula suggested we use MHA/SB thiol to modify the gold nanoparticles. MHA has a long-chain hydrocarbon, which forms a monolayer on the gold nanoparticles, and therefore, has a lower tendency for specific absorption. Meanwhile, the EDC/NHS approach still can be applied to the carboxylic group from MHA for further interaction with peptides. Thus, we decided to modify our gold nanoparticles with MHA/SB thiol.</p>
 
                 <p>Dr. Guthula suggested we use MHA/SB thiol to modify the gold nanoparticles. MHA has a long-chain hydrocarbon, which forms a monolayer on the gold nanoparticles, and therefore, has a lower tendency for specific absorption. Meanwhile, the EDC/NHS approach still can be applied to the carboxylic group from MHA for further interaction with peptides. Thus, we decided to modify our gold nanoparticles with MHA/SB thiol.</p>
Line 278: Line 277:
 
                 </div>
 
                 </div>
 
             </ol>
 
             </ol>
            <br>
 
 
             <p>The picture below shows the evolution of our methods on modifying gold nanoparticles:</p>
 
             <p>The picture below shows the evolution of our methods on modifying gold nanoparticles:</p>
 
             <br>
 
             <br>
Line 284: Line 282:
 
                 <img id="imginfo4" src="https://static.igem.org/mediawiki/2020/b/b6/T--CCU_Taiwan--HP_3_6.png">
 
                 <img id="imginfo4" src="https://static.igem.org/mediawiki/2020/b/b6/T--CCU_Taiwan--HP_3_6.png">
 
             </div>
 
             </div>
            <br>
 
 
             <p><b>Abbreviations:</b> CM-Dextran: carboxymethyl-dextran; MHA: mercaptohexadecanoic acid; SB thiol: 1-(2-sulfosulfanylethylamino)tetradecane; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; NHS: N-hydroxysuccinimide</p>
 
             <p><b>Abbreviations:</b> CM-Dextran: carboxymethyl-dextran; MHA: mercaptohexadecanoic acid; SB thiol: 1-(2-sulfosulfanylethylamino)tetradecane; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; NHS: N-hydroxysuccinimide</p>
 
             <br>
 
             <br>

Revision as of 18:59, 27 October 2020

Integrated Human Practice